On Wednesday, Medtronic , Inc. (NYSE: MDT), a global leader in medical technology, services, and solutions, saw its stock price target increased to $90 from $82 by a Baird analyst. The firm has maintained a Neutral rating on the stock despite the adjustment in the stock target price.
The company has reported its seventh consecutive quarter of mid-single-digit (MSD) revenue growth and has also surpassed adjusted earnings per share (EPS) expectations, with operating margin (OM) results meeting projections. Looking ahead to fiscal year 2025, the analyst anticipates stable MSD revenue growth, driven in part by the introduction of new products such as PFA, 780/Simplera, EV-ICD, and Hugo.
While acknowledging the ongoing foreign exchange (FX) and macroeconomic pressures, the analyst expects such FX pressures to subside in the second half of fiscal year 2025. Moreover, share buybacks are projected to play a more significant role in driving growth acceleration.
Although the firm's calculations suggest a slightly lower operating margin for FY25 than previously estimated, the expected high-single-digit (HSD) EPS growth rate at the end of FY25 is considered a positive indicator for future performance.
The analyst's stance remains cautious until there is clearer visibility on margin stabilization and a resurgence in EPS growth. As a result, the firm advises maintaining a position on the sidelines for the time being, despite the positive growth indicators and strategic initiatives that Medtronic is undertaking.
In other recent news, Medtronic Inc (NYSE:MDT). reported robust first-quarter 2025 revenue of $8.0 billion, a 5.3% organic increase, surpassing expectations. The company's highest-grossing businesses saw an 8% growth, leading to a raise in full-year revenue and EPS guidance.
Amidst this financial growth, Medtronic announced a global partnership with Abbott and appointed Gary Corona as the Interim CFO. However, despite these achievements, Deutsche Bank (ETR:DBKGn) maintained its Hold rating on Medtronic, noting that the updated guidance was roughly equivalent to the first quarter's earnings beat.
Similarly, Wolfe Research maintained its Underperform rating on Medtronic, citing competitive pressures and the company's historical growth rates. Wells Fargo (NYSE:WFC), on the other hand, maintained its Overweight rating on Medtronic due to the company's strong revenue performance, revising its full-year 2025 revenue estimate to $33.6 billion. These are among the recent developments for Medtronic Inc.
InvestingPro Insights
Recent data from InvestingPro underscores the financial robustness and strategic initiatives of Medtronic (NYSE: MDT). The company boasts a solid market capitalization of $109.51 billion, reflecting its significant presence in the healthcare equipment and supplies industry.
With a price-to-earnings (P/E) ratio of 28.57 and an adjusted P/E ratio for the last twelve months as of Q4 2024 at 22.94, Medtronic is positioned as a profitable enterprise, as further evidenced by its revenue of $32.36 billion during the same period. The company's gross profit margin stands at an impressive 65.73%, showcasing its efficiency in maintaining profitability.
InvestingPro Tips highlight Medtronic's shareholder-friendly actions, such as management's aggressive share buybacks and a consistent track record of raising its dividend for 10 consecutive years, with dividend payments maintained for an impressive 48 years.
These actions, combined with a low price volatility and the company's status as a prominent player in its industry, offer insights into Medtronic's stable financial management and commitment to shareholder value. For more detailed analysis and additional tips, investors can explore InvestingPro, which features a total of 10 InvestingPro Tips for Medtronic.
With analysts predicting profitability this year and the stock trading near its 52-week high, Medtronic's strategic direction appears to align with the positive outlook shared by the Baird analyst. The company's commitment to innovation and growth, as well as its stable financial indicators, could provide investors with a clearer picture of its potential trajectory in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.